Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Next Science Ltd ( (AU:NXS) ) has shared an announcement.
Next Science Limited has secured an ASX waiver from Listing Rule 7.25, allowing it to proceed with a planned capital return that may lower its share price below A$0.20, a critical step given the stock’s current trading range of A$0.055 to A$0.155. Following the completion of a US$50 million sale of substantially all of its assets to OSARTIS GmbH, the company intends to seek shareholder approval at an extraordinary general meeting in January 2026 for an interim capital return of surplus funds, a move that advances its wind-down process and would not have been possible without the waiver.
The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science Limited, formerly a medical technology company focused on anti-biofilm and infection control products, has sold substantially all of its assets and those of its wholly owned subsidiaries to OSARTIS GmbH for US$50 million and has applied for removal from the ASX official list, effectively transitioning away from operating its previous core business.
Average Trading Volume: 232,616
Technical Sentiment Signal: Sell
Current Market Cap: A$40.97M
For a thorough assessment of NXS stock, go to TipRanks’ Stock Analysis page.